Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 277 of 5804
-
One-Size-Fits-No-Brain: personalized ICU care tested
Disease control Not yet recruitingAfter severe traumatic brain injury, adequate blood flow to the brain is essential for recovery. This depends on arterial blood pressure, yet intensive care units apply fixed targets to all patients - treating every brain and patient the same. This study aims to change that. With…
Phase: NA • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New Imaging-Guided radiation aims to better control High-Risk prostate cancer
Disease control Not yet recruitingIn this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starti…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
AI spots hidden heart risk in old scans, prompts better treatment
Disease control Not yet recruitingThis multi-site study will test whether an opportunistic AI-based CAC screening and notification intervention can improve cholesterol treatment and lower cholesterol levels in adults. The study uses artificial intelligence to detect calcium buildup in heart arteries (coronary art…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to fight returning brain tumors
Disease control Not yet recruitingApproximately 58-68 total subjects will be enrolled. In the first stage, 10 response evaluable subjects (either IDHwt or IDHm Grade 4 astrocytoma) will be enrolled. If 1 or more of the first 10 response evaluable subjects achieve an objective response, 19 further subjects may be …
Phase: PHASE1, PHASE2 • Sponsor: Starlight Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy aims to personalize throat cancer treatment
Disease control Not yet recruitingThis single-arm Phase I/II trial evaluates induction chemoimmunotherapy combined with lattice radiotherapy (LRT) in patients with non-low risk oropharyngeal squamous cell carcinoma and primary tumor ≥3 cm or primary tumor and pathologic lymph node ≥3 cm in longest dimension. BOIN…
Phase: PHASE1, PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Scientists use patients' own lung fluid cells to fight advanced cancer
Disease control Recruiting nowThis research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's…
Phase: PHASE1 • Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail targets brain tumors from lung and breast cancer
Disease control TerminatedBrain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of primary malignant brain tumors. Over 80% of patients …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New shot could tame inherited high cholesterol
Disease control Not yet recruitingThis Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Stem cells aim to soothe dry eyes in transplant patients
Disease control Not yet recruitingThis Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host Disease (GVHD) and severe ocular involvement (DYD-dry eye…
Phase: PHASE2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to boost depression treatment success
Symptom relief Recruiting nowRepetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough breast cancers: smart switch to targeted drug combo
Disease control Not yet recruitingThis is a multicenter, two-arm, exploratory clinical study designed to evaluate the efficacy and safety of a response-guided neoadjuvant treatment strategy in patients with HER2-positive early or locally advanced breast cancer. Breast cancer is the most common malignancy in wome…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New heart valve offers hope for patients with severe leaky heart
Disease control Not yet recruitingThe goal of this clinical trial is to assess if the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation (TRICENTO G2 TVSTR) is safe and efficient in treating severe tricuspid regurgitation in adult patients. The main questions it aims to answer are: * Does the tr…
Phase: NA • Sponsor: Medira GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to cut opioid use after heart and Weight-Loss surgery
Symptom relief Recruiting nowThis is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of drugs targets tough lymphoma in seniors
Disease control Not yet recruitingThis is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Brain cell injection offers new hope for advanced Parkinson's patients
Disease control Not yet recruitingThis clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have previously undergone deep brain stimulation or deep brai…
Phase: PHASE1 • Sponsor: iRegene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingEnvafolimab is a novel PD-L1 inhibitor administered via subcutaneous (SC) injection - notably the first such checkpoint inhibitor approved for use worldwide.\[1\] In November 2021, Envafolimab received its first approval in China for adults with advanced microsatellite instabilit…
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Sound waves could open Brain's barrier to fight deadly tumor
Disease control Not yet recruitingThis study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a deep part of the brainstem. These tumors are very difficult to treat because they grow into surrounding brain tissue and …
Phase: PHASE1, PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New baby vaccine could fight pneumonia
⭐️ VACCINE ⭐️ Not yet recruitingA Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac P…
Phase: PHASE3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
-
New risk model may let some NPC patients avoid unnecessary chemo
Disease control Recruiting nowThis study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Currently, many high-risk patients receive additional treatment (adjuvant therapy) after standard chemoradiotherapy to prevent the cancer from re…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours. Currently, these patients have a poor prognosis an…
Phase: PHASE1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC